Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Biogen Inc Cmn (BIIB) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 59,347,380
  • Shares Outstanding, K 215,950
  • Annual Sales, $ 11,449 M
  • Annual Income, $ 3,703 M
  • 36-Month Beta 0.79
  • Price/Sales 5.19
  • Price/Cash Flow 11.65
  • Price/Book 4.90

Price Performance

See More
Period Period Low Period High Performance
1-Month
272.34 +1.00%
on 03/27/17
298.00 -7.70%
on 03/03/17
-16.07 (-5.52%)
since 02/27/17
3-Month
250.02 +10.02%
on 01/25/17
298.00 -7.70%
on 03/03/17
+6.91 (+2.58%)
since 12/27/16
52-Week
205.43 +33.90%
on 06/27/16
307.33 -10.50%
on 08/02/16
+40.46 (+17.25%)
since 03/24/16

Most Recent Stories

More News
Stock Market News for March 24, 2017

Benchmarks finished in the red on Thursday following a delay in voting on the new healthcare law introduced by Republicans

KBH : 19.30 (-1.58%)
ALK : 94.92 (+0.23%)
AAPL : 140.80 (+0.11%)
T : 41.53 (-0.36%)
CVX : 106.67 (-1.22%)
SLB : 76.83 (-0.17%)
AMGN : 165.93 (+0.11%)
GME : 20.95 (+1.21%)
BIIB : 274.83 (unch)
Biotech Stock Roundup: Amgen Down on Repatha Data, Nektar Surges on Pain Results

Biotech stocks were hit by the 2018 budget blueprint as well as news on companies like Amgen (AMGN) and Biogen.

CTMX : 18.66 (+4.89%)
ARRY : 9.37 (-0.95%)
GILD : 67.58 (+0.10%)
REGN : 382.86 (+2.64%)
AMGN : 165.93 (+0.11%)
BIIB : 274.83 (unch)
NKTR : 22.57 (+0.67%)
3 Biotech Stocks That Are Broker Favorites

These 3 biotech stocks have been given a Strong Buy or Buy rating by 80% or more brokers and sport a favorable Zacks Rank #1 (Strong Buy) or #2 (Buy).

BPMC : 43.61 (-0.81%)
AMGN : 165.93 (+0.11%)
MATN : 0.7060 (+0.09%)
BIIB : 274.83 (unch)
CLLS : 23.66 (+2.91%)
Trump, Biogen and Amgen Hammer Healthcare ETFs

After making a strong comeback in February, the U.S. healthcare sector again witnessed some pain in the last couple of sessions.

CELG : 125.90 (+2.04%)
XLV : 74.52 (+0.31%)
VHT : 137.84 (+0.33%)
MDCO : 51.03 (+0.67%)
IBB : 292.74 (+0.92%)
PFE : 34.23 (+0.68%)
ESPR : 38.23 (-1.82%)
BBP : 37.73 (+0.96%)
XPH : 41.93 (+2.17%)
ABT : 44.68 (-0.11%)
TMO : 154.87 (+0.54%)
PJP : 59.41 (+1.52%)
IYH : 155.96 (+0.35%)
AMG : 158.50 (-0.23%)
BIIB : 274.83 (unch)
Trump, Biogen and Amgen Hammer Healthcare ETFs

After making a strong comeback in February, the U.S. healthcare sector again witnessed some pain in the last couple of sessions.

CELG : 125.90 (+2.04%)
XLV : 74.52 (+0.31%)
VHT : 137.84 (+0.33%)
MDCO : 51.03 (+0.67%)
IBB : 292.74 (+0.92%)
PFE : 34.23 (+0.68%)
ESPR : 38.23 (-1.82%)
BBP : 37.73 (+0.96%)
XPH : 41.93 (+2.17%)
ABT : 44.68 (-0.11%)
TMO : 154.87 (+0.54%)
PJP : 59.41 (+1.52%)
IYH : 155.96 (+0.35%)
AMG : 158.50 (-0.23%)
BIIB : 274.83 (unch)
Alkermes Starts Phase III Study to Treat Multiple Sclerosis

Alkermes plc (ALKS) announced the initiation of a new phase III study of pipeline candidate ALKS 8700.

HSKA : 98.67 (-0.05%)
ACOR : 26.25 (+3.35%)
ALKS : 58.70 (-0.31%)
BIIB : 274.83 (unch)
Stock Market News for March 17, 2017

Benchmarks finished mostly in the red on Thursday after declines in healthcare and energy stocks outpaced gains in financials sectors

TIF : 95.25 (-0.14%)
GOOGL : 836.06 (+0.11%)
CVX : 106.67 (-1.22%)
AMGN : 165.93 (+0.11%)
BIIB : 274.83 (unch)
Biogen Idec Falls 5.15% on Heavy Volume: Watch For Potential Rebound

Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $275.70 to a high of $285.43. Yesterday, the shares fell 5.1%, which took the trading range below the 3-day low of $289.39...

BIIB : 274.83 (unch)
SmarTrend Watching for Potential Rebound in Shares of Biogen Idec After 5.15% Loss

Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $275.70 to a high of $285.43. Yesterday, the shares fell 5.1%, which took the trading range below the 3-day low of $289.39...

BIIB : 274.83 (unch)
Acorda's Four Ampyra Patents Upheld by PTAB, Shares Rise

U.S. Patent and Trademark Office (USPTO) Patent Trials and Appeal Board (PTAB) upheld four patents of Acorda's key growth driver, Ampyra.

MYL : 41.39 (+1.05%)
AGN : 240.38 (+1.29%)
ACOR : 26.25 (+3.35%)
BIIB : 274.83 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia,...

See More

Support & Resistance

2nd Resistance Point 280.49
1st Resistance Point 277.66
Last Price 274.83
1st Support Level 272.43
2nd Support Level 270.03

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.